BREAKING: Chance Pharmaceuticals has just announced a pivotal commercialization agreement with Huadong Medicine to launch the innovative respiratory drug CXG87 in Mainland China. This strategic partnership, revealed on October 9, 2025, positions Chance Pharma as the Marketing Authorization Holder (MAH) for CXG87, which aims to revolutionize treatment for asthma patients.
This urgent development comes as the Phase III clinical trial for CXG87 has successfully completed enrollment. A New Drug Application (NDA) is set to be submitted in the first half of 2026, marking a significant step towards making this cutting-edge therapy available to millions suffering from respiratory diseases.
Why This Matters NOW: CXG87 is an improved therapy based on budesonide/formoterol powder, designed to reduce flow rate dependency, making it more accessible for patients with impaired inspiratory flow. Mr. Liang Lv, Chairman of Huadong Medicine, emphasized the drug’s potential, stating,
“This partnership will strategically enhance our respiratory pipeline and enable CXG87 to achieve rapid market access and broad coverage upon launch.”
The collaboration will see Chance Pharma manage R&D, registration, manufacturing, and supply, while Huadong Medicine will spearhead commercialization and marketing efforts. This dual approach is expected to expedite the drug’s availability, ensuring patients can access its significant clinical benefits promptly.
In 2024, Huadong Medicine reported revenues of RMB 41.9 billion and has established a robust commercial network across China. Dr. Donghao Chen, CEO of Chance Pharma, noted,
“Our collaboration with Huadong Medicine is a testament to CXG87’s significant commercial potential and will maximize its value for patients.”
CXG87 is a Class 2.2 new drug that promises to enhance asthma treatment options. By utilizing a mono-dose inhaler that minimizes operational errors, the drug aims to provide a more user-friendly experience for patients, thus improving therapeutic outcomes.
The urgency surrounding this announcement is palpable as asthma affects millions worldwide. The collaboration between Chance Pharma and Huadong Medicine could significantly impact respiratory health in China.
As the situation develops, stakeholders in the pharmaceutical and healthcare industries will be closely monitoring the progress of CXG87’s approval and market entry. The partnership represents a significant leap forward in addressing the critical need for effective asthma therapies.
Stay tuned for further updates as Chance Pharmaceuticals and Huadong Medicine work towards bringing this promising treatment to the market. The implications for patient care and the respiratory treatment landscape are immense, making this a story to watch closely.
